Bressler SB, et al. - A sum of 660 candidates with median age 61 years were assessed to evaluate the factors and their interactions related to vision and anatomic consequences while managing diabetic macular edema (DME) with anti-vascular endothelial growth factor (anti-VEGF) between August 22, 2012, and August 28, 2013. Researchers observed an association of decline in hemoglobin A1c level with improvement in vision following the anti-VEGF therapy. They guessed prominent improvement in visual acuity (VA) among younger individuals and those without prior panretinal photocoagulation (PRP) as compared to elders or those with prior PRP.